New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > LEU CLL - ibrutinib

LEU CLL - ibrutinib

Treatment Overview

Cycle 1 (and all further cycles) - 30 days

Cycle length:
30

Cycle details

Cycle 1 (and all further cycles) - 30 days

Medication Dose Route Days Max Duration
ibrutinib 420 mg flat dosing Once daily oral administration 1 to 30

Full details

Cycle 1 (and all further cycles) - 30 days

Day: 1

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 2

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 3

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 4

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 5

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 6

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 7

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 8

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 9

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 10

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 11

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 12

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 13

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 14

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 15

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 16

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 17

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 18

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 19

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 20

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 21

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 22

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 23

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 24

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 25

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 26

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 27

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 28

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 29

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Day: 30

Medication Dose Route Max duration Details
ibrutinib 420 mg flat dosing Once daily oral administration
Instructions:
Swallow capsules whole with a glass of water. Avoid grapefruit or grapefruit juice and Seville oranges as they may interact with this medicine. Discuss with your pharmacist.

Supportive Care Factors

Factor Value
Antiviral prophylaxis for herpes virus: Routine antiviral prophylaxis may be considered
Emetogenicity: Minimal to low
Pneumocystis jirovecii pneumonia (PJP) prophylaxis: Routine antibiotic prophylaxis may be considered
Tumour lysis syndrome prophylaxis: Tumour lysis syndrome prophylaxis may be considered

Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.

References

Byrd, J. C., J. R. Brown, S. O'Brien, et al. 2014. "Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia." N Engl J Med 371(3):213-223., PMID: 24881631

Byrd, J.C., P. Hillmen, S. O'Brien, et al. 2019. "Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab." Blood. 2019 May 9;133(19):2031-2042., PMID: 30842083

Burger, J. A., A. Tedeschi, P. M. Barr, et al. 2015. "Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia." N Engl J Med 373(25):2425-2437., PMID: 26639149

Burger, J.A., P.M. Barr, T. Robak, et al. 2019. "Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study." Leukemia. 2019 Oct 18., PMID: 31628428

Shanafelt T.D., X.V. Wang, N.E. Kay, et al. 2019. "Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia". N Engl J Med. 2019 Aug 1;381(5):432-443., PMID: 31365801

Woyach J.A., A.S. Ruppert, N.A. Heerema, et al. 2018. "Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL". N Engl J Med. 2018 Dec 27;379(26):2517-2528., PMID: 30501481

Woyach, J. A., K. Smucker, L. L. Smith, et al. 2014. "Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy." Blood 123(12):1810-1817., PMID: 24415539

Byrd, J. C., R. R. Furman, S. E. Coutre, et al. 2015. "Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib." Blood 125(16):2497- 2506., PMID: 25700432

Farooqui, M. Z., J. Valdez, S. Martyr, et al. 2015. "Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial." Lancet Oncol 16(2):169-176., PMID: 25555420

O'Brien, S., J. A. Jones, S. E. Coutre, et al. 2016. "Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study." Lancet Oncol 17(10):1409-1418., PMID: 27637985

Janssen-Cilag (New Zealand) Ltd. Imbruvica New Zealand Data Sheet. 30 August 2021. https://www.medsafe.govt.nz/profs/datasheet/I/Imbruvicacap.pdf (accessed 14 December 2021).

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.